UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported) January 9, 2026

Date of Report (Date of earliest event reported) October 30, 2025

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

~~1-15525~~

~~36-4316614~~

1-15525

36-4316614

(State or other jurisdiction of incorporation)

(Commission file number)

(IRS Employer Identification No.)

(State or other jurisdictionof incorporation)

(Commissionfile number)

(IRS EmployerIdentification No.)

One Edwards Way

Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 250-2500

(Registrant’'s telephone number, including area code)

N/A (Former name or former address, if changed since last report)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradingSymbol(s)~~	Trading Symbol(s)	~~Name of each exchangeon which registered~~		Name of each exchange on which registered
Common Stock, par value $1.00 per share		EW	EW	~~New York Stock Exchange~~		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

IfItem an7.01. ~~emerging~~Other growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange ActEvents. ☐

~~Item~~On 5January 9, 2026 Edwards Lifesciences Corporation (the “Company”) issued a press release announcing that the United States District Court for the District of Columbia has granted the motion from the U.02S. ~~Departure~~Federal ofTrade ~~Directors~~Commission orfor ~~Certain~~an ~~Officers;~~injunction ~~Election~~blocking ofthe ~~Directors;~~Company’s ~~Appointment~~proposed acquisition of ~~Certain~~JenaValve ~~Officers;~~Technology, ~~Compensatory~~Inc ~~Arrangements~~(“JenaValve”). ofAs ~~Certain~~a ~~Officers~~result, the Company will not acquire JenaValve.

OnA ~~October 30~~copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, ~~2025~~the information in this Item 7.01, ~~Scott~~including ~~Ullem~~Exhibit 99.1, ~~the~~shall ~~Chief~~not ~~Financial~~be ~~Officer~~deemed to be “filed” for purposes of ~~Edwards~~Section ~~Lifesciences~~18 ~~Corporation,~~of athe ~~Delaware~~Securities ~~corporation~~Exchange Act of 1934, as amended (the “~~Corporation~~Exchange Act”), ~~informed~~or otherwise subject to the ~~Corporation~~liabilities of ~~his~~that ~~decision~~section, toand ~~transition~~shall ~~from~~not ~~his~~be ~~role~~incorporated by ~~mid-year~~reference ~~2026.~~into Onany ~~October 30,~~registration ~~2025,~~statement or other document filed under the ~~Corporation~~Securities ~~issued~~Act aof ~~press~~1933, ~~release~~as ~~announcing~~amended, ~~his~~or ~~decision.~~the ~~The~~Exchange ~~Corporation~~Act, isexcept ~~initiating~~as ashall ~~selection~~be ~~process~~expressly toset ~~appoint~~forth aby ~~new~~specific ~~Chief~~reference ~~Financial~~in ~~Officer.~~such filing.

Item 7.01. Regulation FD Disclosure.

On October 30, 2025, the Corporation issued a press release announcing a CFO transition plan. A copy of the press release is filed as Exhibit 99.1, and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



(d)						Exhibits

99.1						Press Release of Edwards Lifesciences Corporation, dated as of January 9, 2026.

104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

99.1		Press Release, issued on October 30, 2025, announcing CFO transition plan.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~EDWARDS LIFESCIENCES CORPORATION~~

EDWARDS LIFESCIENCES CORPORATION

~~By:~~

~~/s/ Mark D. Peterson~~By:

/s/ Mark D. Peterson

~~Mark D. Peterson~~

Mark D. Peterson

Date: October 30, 2025

CVP, General Counsel

Date: January 9, 2026

Corporate Vice President, General Counsel

Filing Compare · Edwards Lifesciences Corp